Phase III is intended to generate meaningful biological data on potential drug compounds prioritized by YuvaBio’s classifier, which applies proprietary machine-learning methods to identify candidates targeting muscle preservation through improvements in mitochondrial function.Experimental work designed to identify candidates that may upregulate ANT1, a key gene involved in metabolic function and muscle integrity.Phase III is expected to accelerate discovery on small-molecule candidates which may promote mit ...

Core Insights - Northstrive Biosciences Inc. has completed Phase II of its AI Development Program in collaboration with Yuva Biosciences, focusing on small molecule candidates to promote mitochondrial health for combating obesity and cardiac diseases [1][6] Company Overview - Northstrive Biosciences Inc. is a biopharmaceutical company under PMGC Holdings Inc., specializing in the development of aesthetic medicines, with its lead asset EL-22 aimed at preserving muscle during weight loss treatments [3] - PMGC Holdings Inc. is a diversified holding company that manages a portfolio through strategic acquisitions and investments across various industries [4] Collaboration Details - YuvaBio completed Phase II by compiling a targeted collection of compounds from 12 curated libraries, focusing on obesity, cardiometabolic disorders, and lipid & glucose metabolism [2] - The MitoNova™ AI platform was utilized to screen compounds for their potential impact on muscle preservation and metabolic health, resulting in a shortlist of candidates for biological validation [2][6]